Media item displaying Ben Picozzi

Ben Picozzi

Partner

[email protected]

202.434.5266

Ben is a member of the firm’s Patent Litigation group and focuses his practice on the pharmaceutical industry.  As part of that practice, he has represented clients at all stages of litigation, from providing pre-litigation advice to serving and as trial and lead appellate counsel.  Ben is also registered to practice before the U.S. Patent & Trademark Office and has represented clients in prosecuting and defending inter partes review challenges.

Ben was born and raised in Seattle, Washington, and graduated with distinction and honors from Stanford University in 2010.  He received his J.D. from Yale Law School, where he was an Articles Editor for the Yale Law Journal and won numerous awards for legal writing.

Ben joined Williams & Connolly in 2017, after serving as a law clerk to the Honorable Richard G. Taranto of the U.S. Court of Appeals for the Federal Circuit.

Experience

Though all cases vary and none is predictive, Ben’s experience includes:

  • Counsel for Teva’s Branded Division in Hatch-Waxman litigation in the District of Delaware regarding Teva’s Bendeka® anti-cancer treatment.  After a seven-day bench trial, the district court ruled for Teva on the infringement and validity of all five patents.  The Federal Circuit affirmed on appeal.
  • Counsel for Bayer CropScience and Monsanto in patent litigation in the District of Delaware and three related inter partes review proceedings.  The Patent Trial and Appeal Board issued three final written decisions in Bayer’s favor, resulting in a stay of the district-court litigation.
  • Counsel for Pfizer in patent litigation regarding Pfizer’s Paxlovid® COVID-19 treatment.  The district court granted summary judgment of invalidity in Pfizer’s favor.
  • Counsel for Teva’s Branded Division in Hatch-Waxman litigation in the District Court in the District of New Jersey involving Teva’s QVAR® anti-asthma treatment and lead appellate counsel.  The district court found for Teva on all issues following a bench trial.
  • Counsel for Teva’s Branded Division in Hatch-Waxman litigation in the District of New Jersey involving Teva’s QVAR® RediHaler® anti-asthma treatment.
  • Counsel for AstraZeneca in licensing dispute involving breach of contract claims.
  • Counsel for Bayer in Hatch-Waxman litigation regarding Bayer’s Stivarga® anti-cancer treatment.

News & Insights

All News & Insights